BRPI0513953A - métodos para tratamento de doenças ou distúrbios mediados pela ccr2 - Google Patents
métodos para tratamento de doenças ou distúrbios mediados pela ccr2Info
- Publication number
- BRPI0513953A BRPI0513953A BRPI0513953-8A BRPI0513953A BRPI0513953A BR PI0513953 A BRPI0513953 A BR PI0513953A BR PI0513953 A BRPI0513953 A BR PI0513953A BR PI0513953 A BRPI0513953 A BR PI0513953A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- ccr2
- disorders
- treating
- patients
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 208000035475 disorder Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 abstract 4
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 229940124597 therapeutic agent Drugs 0.000 abstract 4
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 235000013330 chicken meat Nutrition 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000013372 meat Nutrition 0.000 abstract 1
- 238000003307 slaughter Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59268304P | 2004-07-30 | 2004-07-30 | |
| PCT/IB2005/002162 WO2006013427A2 (en) | 2004-07-30 | 2005-07-18 | Treatment of ccr2 mediated diseases or disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0513953A true BRPI0513953A (pt) | 2008-05-20 |
Family
ID=35207829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0513953-8A BRPI0513953A (pt) | 2004-07-30 | 2005-07-18 | métodos para tratamento de doenças ou distúrbios mediados pela ccr2 |
Country Status (14)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7671062B2 (en) | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
| US7629351B2 (en) | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
| US7687508B2 (en) | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| RU2547595C2 (ru) | 2008-08-18 | 2015-04-10 | Пфайзер Инк | Антитела против ccr2 |
| US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| US9726666B2 (en) | 2011-06-13 | 2017-08-08 | Tla Targeted Immunotherapies Ab | Diagnosing and treating inflammatory diseases |
| ES2636679T3 (es) * | 2011-06-27 | 2017-10-06 | Université Pierre Et Marie Curie (Paris 6) | Péptidos antagonistas de CCR2 |
| WO2022235440A1 (en) * | 2021-04-21 | 2022-11-10 | The United States Government As Represented By The Department Of Veterans Affairs | Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| FR2792837B1 (fr) * | 1999-04-29 | 2001-07-13 | Centre Nat Rech Scient | Medicaments utiles pour le traitement des troubles de la regulation de la masse adipeuse et des maladies associees aux troubles de la production de leptine |
| US20050245537A1 (en) * | 2002-04-24 | 2005-11-03 | Noboru Tsuchimori | Use of compounds having ccr antagonism |
| EP1646392A4 (en) * | 2003-07-15 | 2007-02-28 | Merck & Co Inc | 7- and 8-membered heterocyclic cyclopentyl-benzylamide modulators of the chemokine-receptor activity |
| KR20080052683A (ko) * | 2003-12-18 | 2008-06-11 | 인사이트 코포레이션 | 케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체 |
-
2005
- 2005-07-18 MX MX2007001204A patent/MX2007001204A/es unknown
- 2005-07-18 RU RU2007103332/14A patent/RU2007103332A/ru not_active Application Discontinuation
- 2005-07-18 BR BRPI0513953-8A patent/BRPI0513953A/pt not_active IP Right Cessation
- 2005-07-18 KR KR1020087010937A patent/KR20080044360A/ko not_active Ceased
- 2005-07-18 CA CA002575612A patent/CA2575612A1/en not_active Abandoned
- 2005-07-18 JP JP2007523167A patent/JP2008508253A/ja not_active Withdrawn
- 2005-07-18 CN CNA2005800276608A patent/CN101005855A/zh active Pending
- 2005-07-18 WO PCT/IB2005/002162 patent/WO2006013427A2/en not_active Ceased
- 2005-07-18 AU AU2005268545A patent/AU2005268545A1/en not_active Abandoned
- 2005-07-18 EP EP05777347A patent/EP1778285A2/en not_active Withdrawn
- 2005-09-16 US US11/658,989 patent/US20090196823A1/en not_active Abandoned
-
2007
- 2007-01-11 IL IL180675A patent/IL180675A0/en unknown
- 2007-01-29 ZA ZA200700823A patent/ZA200700823B/xx unknown
- 2007-02-21 NO NO20070996A patent/NO20070996L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007103332A (ru) | 2008-08-10 |
| KR20080044360A (ko) | 2008-05-20 |
| WO2006013427A3 (en) | 2006-06-08 |
| CN101005855A (zh) | 2007-07-25 |
| ZA200700823B (en) | 2008-10-29 |
| CA2575612A1 (en) | 2006-02-09 |
| NO20070996L (no) | 2007-04-23 |
| US20090196823A1 (en) | 2009-08-06 |
| EP1778285A2 (en) | 2007-05-02 |
| MX2007001204A (es) | 2007-03-23 |
| WO2006013427A2 (en) | 2006-02-09 |
| IL180675A0 (en) | 2007-06-03 |
| JP2008508253A (ja) | 2008-03-21 |
| AU2005268545A1 (en) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511854A (pt) | inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica | |
| Belujon et al. | Dopamine system dysregulation in major depressive disorders | |
| BRPI0606707A2 (pt) | uréias dissubstituìdas como inibidores de quinase | |
| BRPI0401768A (pt) | Método de tratamento de um animal não-humano, e, método para reduzir a ocorrência de febre de transporte de gado bovino | |
| BR0317747A (pt) | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave | |
| BR0011823A (pt) | Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo | |
| Bradley | Psychiatric comorbidity in fibromyalgia | |
| BRPI0206432A2 (pt) | métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento | |
| BR112017009678A2 (pt) | composição optimizada de nutrientes de ácidos graxos e método de preparação da mesma | |
| BRPI0712561B8 (pt) | Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida | |
| BRPI0513953A (pt) | métodos para tratamento de doenças ou distúrbios mediados pela ccr2 | |
| Maillaud et al. | Is stonefish Synanceia verrucosa envenomation potentially lethal? | |
| BR0211145A (pt) | Composição de alimento para animais de estimação para regular o peso corporal e prevenir a obesidade e distúrbios relacionados em animais de estimação | |
| BRPI0502691A (pt) | composição farmacêutica para o controle da glicose no sangue de pacientes com diabetes tipo 2 | |
| Ramzan | The racehorse: A veterinary manual | |
| Anz et al. | Animals as healers: A historical journey through the impact of animals on human health across the ages | |
| BR112017023493A2 (pt) | composições que compreendem cinamaldeído e zinco e métodos de uso de tais composições | |
| Dallé et al. | Anti-parkinsonian effects of fluvoxamine maleate in maternally separated rats | |
| Harikrishnan | Anaesthesia, analgesia and euthanasia of laboratory rodents and rabbits: a practical approach | |
| RU133721U1 (ru) | Устройство для фиксации перевязочного материала на ожоговой поверхности экспериментального животного | |
| BRPI0416118A (pt) | inibição da fosfodiesterase 9 como tratamento para estados relacionados com a obesidade | |
| León et al. | Effects of chronic intracerebroventricular 3, 4-methylenedioxy-N-methamphetamine (MDMA) or fluoxetine on the active avoidance test in rats with or without exposure to mild chronic stress | |
| CN104825450A (zh) | Dapk1抑制剂在制备抗抑郁药物中的应用 | |
| Sibold et al. | C57 mice increase wheel-running behavior following stress: preliminary findings | |
| Zhou | Traditional Chinese medicine. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |